Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Altered glutamatergic neurotransmission is implicated in the pathogenesis of major depressive disorder. AXS-05 (dextromethorphan-bupropion) is an oral NMDA receptor antagonist and sigma-1 receptor agonist, which utilizes inhibition of CYP2D6 to increase its bioavailability. This phase 2 trial assessed the efficacy and safety of dextromethorphan-bupropion in the treatment of major depressive disorder. METHODS: This randomized, double-blind, multicenter, parallel-group trial evaluated dextromethorphan-bupropion versus the active comparator sustained-release bupropion in patients 18-65 years old with a diagnosis of major depressive disorder of moderate or greater severity. Patients were randomly assigned to receive either dextromethorphan-bupropion (45 mg/105 mg tablet) or bupropion (105 mg tablet), once daily for the first 3 days and twice daily thereafter, for a total of 6 weeks. The primary endpoint was overall treatment effect on Montgomery-Åsberg Depression Rating Scale (MADRS) score (average of the change from baseline for weeks 1-6), assessed in all randomized patients whose diagnosis and severity were confirmed by an independent assessor and who received at least one dose of study medication and had at least one postbaseline assessment. RESULTS: Of 97 patients randomized, 17 did not have a confirmed diagnosis and severity based on the independent assessment, resulting in 80 patients in the efficacy population (dextromethorphan-bupropion, N=43; bupropion, N=37). The mean change from baseline in MADRS score over weeks 1-6 (overall treatment effect) was significantly greater with dextromethorphan-bupropion than with bupropion (-13.7 points vs. -8.8 points; least-squares mean difference=-4.9; 95% CI=-3.1, -6.8). MADRS score change with dextromethorphan-bupropion was significantly greater than with bupropion at week 2 and every time point thereafter (week 6: -17.3 vs. -12.1 points; least-squares mean difference=-5.2, 95% CI=-1.1, -9.3). Remission rates were significantly greater with dextromethorphan-bupropion at week 2 and every time point thereafter (week 6: 46.5% vs. 16.2%; least-squares mean difference=30.3%, 95% CI=11.2, 49.4). Response rates (≥50% decrease in MADRS score from baseline) at week 6 were 60.5% with dextromethorphan-bupropion and 40.5% with bupropion (least-squares mean difference=19.9%, 95% CI=-1.6, 41). Most secondary outcomes favored dextromethorphan-bupropion. The most common adverse events with dextromethorphan-bupropion were dizziness, nausea, dry mouth, decreased appetite, and anxiety. Dextromethorphan-bupropion was not associated with psychotomimetic effects, weight gain, or sexual dysfunction. CONCLUSIONS: In patients with major depression, dextromethorphan-bupropion (AXS-05) significantly improved depressive symptoms compared with bupropion and was generally well tolerated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dextromethorphan’s primary potential for MDD treatment is theorized to be due to its uncompetitive antagonism of the ionotropic glutamate receptor NMDA in the central nervous system [17,18].”
From Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder (2023) · cites this paper as [17]
In the citing paper
“Remission and response rates were significantly higher with dextromethorphan-bupropion in both studies.”
From Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder (2023) · cites this paper as [17]
In the citing paper
“The medication was well-tolerated in both trials, with the most common adverse events being rated as mild-to-moderate.”
From Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder (2023) · cites this paper as [17]
In the citing paper
“Changes in Montgomery–Åsberg Depression Rating Scale with dextromethorphan-bupropion were seen within two weeks in both clinical trials.”
From Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder (2023) · cites this paper as [17]
In the citing paper
“Dextromethorphan-bupropion was assessed for efficacy and safety in treating major depressive disorder (MDD) in a phase 2, randomized, double-blind, active-controlled trial (n = 80) [17].”
From Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder (2023) · cites this paper as [17]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109
Fava, M., & Kendler, K. S. (2000) · Neuron · doi:10.1016/s0896-6273(00)00112-4 · Cited by 603
Fava, M., Evins, A. E., Dorer, D. J., & Schoenfeld, D. A. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000069738 · Cited by 452
The Impact of Treatment-Resistant Depression on Health Care Utilization and Costs
Crown, W. H., Finkelstein, S., Berndt, E. R., Ling, D., Poret, A. W., Rush, A. J., & Russell, J. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1102 · Cited by 386
Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands
Cobos, E., Entrena, J., Nieto, F., Cendan, C., & Pozo, E. (2008) · Current Neuropharmacology · doi:10.2174/157015908787386113 · Cited by 376
Research works printed but not linked: 7
- Saltiel PF, 2015, Neuropsychiatr Dis Treat, 11, 875
- World Health Organization, 2018, Fact Sheets: Depression
- Whitlock ME, 2019, Innov Clin Neurosci, 16, 12
- International Conference on Harmonisation, 2001, J Postgrad Med, 47, 45
- First MB, 2015, Structured Clinical Interview for DSM-5 Disorders Clinical Trials Version (SCID-5-CT)
- Davidson JR, 1998, J Clin Psychiatry, 59, 25
- Keefe RS, 2013, Innov Clin Neurosci, 10, 4S
Cited by
New and emerging approaches to treat psychiatric disorders
Scangos, K. W., State, M. W., Miller, A. H., Baker, J. T., & Williams, L. M. (2023) · Nature Medicine · doi:10.1038/s41591-022-02197-0 · Cited by 179
Koszła, O., & Sołek, P. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01791-8 · Cited by 177
“Additionally, the modified antidepressant drug AXS-05 is in phase III trials and has shown positive effects in treating Sundowner Syndrome in Alzheimer’s patients [117].”
BackgroundQaseem, A., Owens, D. K., Etxeandia‐Ikobaltzeta, I., Tufte, J., Cross, J. T., Wilt, T. J., Crandall, C. J., Balk, E., Cooney, T. G., Fitterman, N., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2056 · Cited by 141
“The CGC is planning to maintain this topic as a living guideline with quarterly literature surveillance and periodic updating of the systematic review and the clinical recommendations, given that the topic is a priority for clinical care and there is active and ongoing research on new and innovative drugs for MDD indi…”
BackgroundCorrell, C. U., Solmi, M., Cortese, S., Fava, M., Højlund, M., KRAEMER, H. C., McIntyre, R. S., Pine, D. S., Schneider, L. S. S., & Kane, J. M. (2023) · World Psychiatry · doi:10.1002/wps.21056 · Cited by 120
Glutamatergic Modulators for Major Depression from Theory to Clinical Use
McIntyre, R. S., & Jain, R. (2024) · CNS Drugs · doi:10.1007/s40263-024-01114-y · Cited by 69
“…quinidine, was investigated in a 2016 phase 2 study for treatment of MDD (NCT02153502); however, the sponsor reported that it halted development of this agent in depression because results of the phase 2 trial did not provide sufficient evidence of efficacy to justify continued development [142].”
BackgroundMethodInfluentialDextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder
McCarthy, B., Bunn, H., Santalucia, M., Wilmouth, C., Muzyk, A., & Smith, C. M. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1081 · Cited by 63
“Dextromethorphan-bupropion was assessed for efficacy and safety in treating major depressive disorder (MDD) in a phase 2, randomized, double-blind, active-controlled trial (n = 80) [17].”
BackgroundLv, S., Yao, K., Zhang, Y., & Zhu, S. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109378 · Cited by 61
Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R. (2023) · Pharmaceuticals · doi:10.3390/ph16111572 · Cited by 48
“Two phase III RCTs have evaluated AXS-05 monotherapy for MDD/TRD, showing favorable safety and tolerability [155].”
BackgroundDextromethorphan/Bupropion: First Approval
Keam, S. J. (2022) · CNS Drugs · doi:10.1007/s40263-022-00968-4 · Cited by 52
“1234 Dextromethorphan/Bupropion: First Approval Key clinical trials of dextromethorphan/bupropion (AXS-05) Drug(s) Indication Phase Status Location(s) Sponsor/Collaborator Identifier AXS-05, placebo MDD 3 Completed USA Axsome Therapeutics NCT04019704; GEMINI; AXS-05MDD-301 AXS-05 MDD 3 Completed USA Axsome Therapeutic…”
BackgroundInfluentialLiu, W., Li, Y., Zhao, T., Gong, M., Wang, X., Zhang, Y., Xu, L., Li, W., Li, Y., & Jia, J. (2023) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2023.102534 · Cited by 46
Clark, A., Tate, B., Urban, B., Schroeder, R., Gennuso, S. A., Ahmadzadeh, S., McGregor, D., Girma, B., Shekoohi, S., & Kaye, A. D. (2023) · Health Psychology Research · doi:10.52965/001c.81043 · Cited by 50
Clinical specificity profile for novel rapid acting antidepressant drugs
Scala, M., Fanelli, G., De Ronchi, D., Serretti, A., & Fabbri, C. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000488 · Cited by 41
“3% of patients treated with AXS05 (Tabuteau et al., 2022) and by 9.”
BackgroundResultInfluentialAkbar, D., Rhee, T. G., Ceban, F., Ho, R., Teopiz, K. M., Cao, B., Subramaniapillai, M., Kwan, A. T. H., Rosenblat, J. D., & McIntyre, R. S. (2023) · CNS Drugs · doi:10.1007/s40263-023-01032-5 · Cited by 38
“Tabuteau et al performed a Phase 2, randomized, doubleblind, active-controlled trial (ASCEND) [25].”
BackgroundMethodInfluentialStructure–Activity Relationship of Synthetic Cathinones: An Updated Review
Nadal‐Gratacós, N., Pazos, M. D., Pubill, D., Camarasa, J., Escubedo, E., Berzosa, X., & López‐Arnau, R. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00299 · Cited by 43
Esmethadone-HCl (REL-1017): a promising rapid antidepressant
Fava, M., Stahl, S. M., Martin, S. D., Mattarei, A., Bettini, E., Comai, S., Alimonti, A., Bifari, F., Pani, L., Folli, F. B., et al. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01571-4 · Cited by 32
“The combination drug dextromethorphan–bupropion is better tolerated than ketamine and esketamine [22] but carries the combined side effects of two different drugs with the burdens of polypharmacy, which may be especially relevant when this combination drug is under consideration for patients who are already taking oth…”
BackgroundMethodBettini, E., Stahl, S. M., De Martin, S., Mattarei, A., Sgrignani, J., Carignani, C., Nola, S., Locatelli, P., Pappagallo, M., Inturrisi, C. E., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15080997 · Cited by 31
“Although temporary dissociative effects occur in most patients treated with racemic ketamine and esketamine at doses currently used to treat MDD, the current consensus is that induction of dissociative effects is not necessary for the rapid antidepressant effects of ketamine [37,38].”
BackgroundInfluentialChaki, S., & Watanabe, M. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109348 · Cited by 30
Classics in Chemical Neuroscience: Dextromethorphan (DXM)
McClure, E. W., & Daniels, R. N. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00088 · Cited by 32
Stahl, S. M., Martin, S. D., Mattarei, A., Bettini, E., Pani, L., Guidetti, C., Folli, F. B., de Somer, M., Traversa, S., Inturrisi, C. E., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012196 · Cited by 24
“Arketamine, because of its four-fold lower potency compared to esketamine, may have the potential to relieve depressive symptoms without causing dissociative side effects [55], similarly to the lower-potency NMDAR l antagonists esmethadone and dextromethorphan [17,18].”
BackgroundInfluentialNovel approaches to clinical trial design in cancer neuroscience
Jones, G., Anderson, J. L., Nguyen, P. T., Gleber‐Netto, F. O., Hwang, W. L., Puduvalli, V. K., Monje, M., & Amit, M. (2025) · Neuron · doi:10.1016/j.neuron.2025.08.015 · Cited by 27
All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants
Freudenberg, F., Reif-Leonhard, C., Dawson, G. R., McKernan, R. M., & Reif, A. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107918 · Cited by 23
Shram, M. J., Henningfield, J. E., Apseloff, G., Gorodetzky, C. W., Martin, S. D., Vocci, F. L., Sapienza, F. L., Kosten, T. R., Huston, J., Buchhalter, A. R., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02473-8 · Cited by 24
“Considering that MDD is a highly prevalent and life-threatening condition and available treatments have limited and delayed efficacy and metabolic and neurological side effects, an unmet need exists for safe, well-tolerated, and rapidly effective antidepressants.”
BackgroundInfluentialCooper, T., Seigler, M. D., & Stahl, S. M. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231158891 · Cited by 23
“However, oral NMDA antagonists such as dextromethorphan (Stahl, 2019; Tabuteau et al., 2022) and esmethadone as well as the GABA A PAMs (Frieder et al., 2019; Meltzer-Brody et al., 2018) do not induce such mental status changes yet are rapid onset plasticity inducers with rapid acting…”
BackgroundLucido, M. J., & Dunlop, B. W. (2025) · Brain Sciences · doi:10.3390/brainsci15020161 · Cited by 23
“A subsequent trial in 80 non-TRD MDD patients compared AXS-05 to equivalent bupropion monotherapy (i.e., 105 mg BID) and also demonstrated the superiority of AXS-05, with sustained statistical separation beginning at week 2 [80].”
Schatzberg, A. F. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220434 · Cited by 20
Antidepressants and Weight Gain: An Update on the Evidence and Clinical Implications
Moss, L., Laudenslager, M., Steffen, K. J., Sockalingam, S., & Coughlin, J. W. (2025) · Current Obesity Reports · doi:10.1007/s13679-024-00598-5 · Cited by 23
“To our knowledge, recent clinical trials have only addressed weight change with the use of dextromethorphan-bupropion (see above under NDRIs), gepirone, and zuranolone [46, 68, 69].”
Anhedonia: Current and future treatments
Serretti, A. (2025) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.70088 · Cited by 39
“42 This Phase 2, randomized, double ‐ blind, active ‐ controlled trial examined AXS ‐ 05 — oral tablet combining dextromethorphan and bupropion — against bupropion SR alone in patients with moderate or greater severity MDD. Eighty patients completed efficacy assessments and treatment lasted 6 weeks.”
Synthetic surprise as the foundation of the psychedelic experience
Filippo, R. D., & Schmitz, D. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105538 · Cited by 19
Awareness of Mental Health Issues in Malaysian Construction Industry
Esa, M. B., Muniandy, P., & Noor, N. A. S. M. (2024) · Journal of Health and Quality of Life · doi:10.37934/hqol.1.1.2148 · Cited by 28
“Tabuteau [40] found that when a worker exhibits depressive symptoms, the likelihood of sustaining an injury increases by over twofold.”
BackgroundMathew, S. J., Cutler, A. J., Visitacion, N. C., Gold, M., Yuan, J. X. ‐., & Aurora, B. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001967 · Cited by 15
Advancements in Drug Repurposing: Examples in Psychiatric Medications
Okuyama, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311000 · Cited by 15
“This fixed-dose combination aims to enhance the sustained effect by prolonging the action of dextromethorphan and by exerting a potent antidepressant effect through the actions of both compounds [29].”
BackgroundSackeïm, H. A., Aaronson, S. T., Bunker, M. T., Conway, C. R., George, M. S., McAllister-Williams, H., Prudic, J., Thase, M. E., Young, A. H., & Rush, A. J. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.05.046 · Cited by 17
Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD)
Olivier, B., & Olivier, J. D. A. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-981-97-4402-2_3 · Cited by 12
Pharmacological Monotherapy for Depressive Disorders: Current and Future—A Narrative Review
Gao, K., Oruc, E. B., & Koparal, B. (2025) · Medicina · doi:10.3390/medicina61040558 · Cited by 14
“The approval was based on one phase II and one phase III randomized, double-blind, placebo-controlled trial [44,45].”
New and emerging pharmacologic treatments for MDD
Uyar, A., & Gönül, A. S. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1621887 · Cited by 19
Jiang, Y., Dong, Y., & Hu, H. (2024) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2023.0225 · Cited by 15
Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression
Freudenberg, F., Reif-Leonhard, C., & Reif, A. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01875-z · Cited by 15
Comai, S., Martin, S. D., Mattarei, A., Guidetti, C., Pappagallo, M., Folli, F. B., Alimonti, A., & Manfredi, P. L. (2024) · Pharmaceuticals · doi:10.3390/ph17121618 · Cited by 14
“Relief from depression without dissociative effects was demonstrated with other NMDAR uncompetitive antagonists, such as the dextromethorphan-bupropion combination [38].”
InfluentialSharma, G., Shukla, R., & Singh, T. R. (2022) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-022-00374-2 · Cited by 11
Nagata, T., Shinagawa, S., Inamura, K., & Shigeta, M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091365 · Cited by 11
Petrozzi, B. P., Deuschle, M., & Gilles, M. (2023) · Clinical Case Reports · doi:10.1002/ccr3.7045 · Cited by 11
The why, when, where, how, and so what of so-called rapidly acting antidepressants
Schatzberg, A. F., & Mathew, S. J. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01647-8 · Cited by 11
“…improvement within 1 week — i.e., rapid onset — based in its having been reported to be signi fi cantly more effective than placebo at 6 weeks in MDD with separation beginning by week one in one Phase III trial [16] and week two in another trial comparing the combination to bupropion alone [17].”
ResultDextromethorphan/Bupropion: A Novel Treatment for Patients With Major Depressive Disorder
Willett, K. C., Bond, L. R., Morrill, A. M., Dima, L., & Ifteni, P. I. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001699 · Cited by 11
Castanheira, S., Gomes, C. V., Bicker, J., & Fortuna, A. C. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104371 · Cited by 11
IsHak, W. W., Hirsch, D., Renteria, S., Totlani, J., Murphy, N., Chang, T. Y., Abdelsalam, R., Salem, M., Meyer, A., Keerthana, S., et al. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07141-3 · Cited by 13
“Adverse Effects : Nausea, dizziness, dry mouth, decreased appetite, anxiety [41, 42].”
Synaptic priming: A framework for pharmacotherapy in depression
Brown, K. A., Ajibola, M. I., Medeiros, G. C., & Gould, T. D. (2025) · Neuron · doi:10.1016/j.neuron.2025.09.010 · Cited by 13
Molecular Mechanisms of Emerging Antidepressant Strategies: From Ketamine to Neuromodulation
Kowalczyk, M., Aebisher, D., Szpara, J., Czech, S., Bartusik‐Aebisher, D., & Henrykowska, G. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010344 · Cited by 11
“…superiority of the combination therapy was evident as early as two weeks after treatment initiation and persisted until the end of the study, accompanied by higher rates of remission and clinical response, as well as consistent improvements in global assessments and patient-reported outcomes [59].”
Grassi, G., Scillitani, E., & Cecchelli, C. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2387127 · Cited by 8
“This combination has been granted approval by the FDA for the management of depression [133,134].”
Combinations of dextromethorphan for the treatment of mood disorders - a review of the evidence
Parincu, Z., & Iosifescu, D. V. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2192402 · Cited by 10
“Several clinical studies demonstrated that dextromethorphan-quinidine with 40 mg dextromethorphan [29] and dextromethorphan-bupropion at 45 mg/ 105 mg [31,32] could reduce depressive symptoms in MDD, with good tolerability and few side effects (e.”
BackgroundMethodResultInfluentialSelf-citationA Critical View on New and Future Antidepressants
Serretti, A. (2024) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1145 · Cited by 13
“Results were very promising in the treatment of depression also in comorbidity with anxiety disorders [19,20].”
BackgroundRecent Developments in Pharmacotherapy of Depression: Bench to Bedside
Shad, M. U. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13050773 · Cited by 11
“In the short-term preclinical trials, dextromethorphan–bupropion was not associated with weight gain or sexual dysfunction, perhaps due to the noradrenergic effects of bupropion [94,100,101].”
BackgroundQiu, Y., Li, L., Duan, A., Wang, M., Xie, M., Chen, Z., & Wang, Z. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06449-w · Cited by 8
“In addition, we also note that several RCTs about drugs related to NMDA inhibitors have been published, but the only interventions we included were N2O and placebo due to the need for more studies that compare N2O and other drugs (Cole et al. 2022; Tabuteau et al. 2022).”
BackgroundChronic stress in mice: how gut bacteria influence gene activity in key brain neurons
Jiang, W., Li, Y., Yang, J., Tan, X., Tian, R., Ma, G., Wu, J., Zhang, J., Huang, Y., Liu, P., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03479-0 · Cited by 8
“Notably, disruptions in glutamatergic neurotransmission and synaptic remodeling are involved in the pathogenesis of depression [55 – 59].”
Current drug targets for the treatment of depression
Pathak, G., Nigade, A., Anitha, K., & Bhatt, S. (2025) · Brain Disorders · doi:10.1016/j.dscb.2025.100270 · Cited by 8
New advances in small molecule drugs targeting NMDA receptors
Zeng, Y., Qu, Z.-Y., Zhu, Q., Wang, H., Zhou, Y., & Gao, Z.-B. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01675-8 · Cited by 9
“Clinically, a Phase II trial (NCT03595579, n = 97) showed signi fi cantly higher remission rates with dextromethorphan-Table bupropion versus bupropion monotherapy [136].”
A scientometric analysis of research on the role of NMDA receptor in the treatment of depression
Chen, X., Wang, X., Li, C., Zhang, Y., Feng, S., & Xu, S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1394730 · Cited by 9
Rethinking the medication management of major depression
Mann, J. J., & Rizk, M. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2190886 · Cited by 10
The sigma–1 receptor: a mechanistically–informed therapeutic target for antidepressants
Xiao, N., Yin, L., Teopiz, K. M., Kwan, A. T. H., Le, G. H., Wong, S., Valentino, K., Choi, H., Rosenblat, J. D., Ho, R., et al. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2500424 · Cited by 6
“At week 6, remission on the QIDS-SR, defined as a score ≤5, was achieved by 46.5% of the dextromethorphan-bupropion group compared to 21.6% of the bupropion group ( p = 0.020) [34].”
InfluentialCarmellini, P., Pinzi, M., Rescalli, M. B., & Cuomo, A. (2025) · Brain Sciences · doi:10.3390/brainsci16010018 · Cited by 7
“Co-formulation with bupropion, a norepinephrine-dopamine reuptake inhibitor and potent CYP2D6 inhibitor, prolongs DXM exposure while contributing additive antidepressant effects [64].”
An Open-Label Study of Adjunctive Dextromethorphan/Quinidine in Treatment-Resistant Depression
Wang, P. R., Yavi, M., Lee, H., Kotb, Y., Shora, L., Park, L. T., & Zarate, C. A. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001738 · Cited by 6
Ferri, N., Martin, S. D., Stuart, J., Traversa, S., Mattarei, A., Comai, S., Folli, F. B., Pappagallo, M., Guidetti, C., Inturrisi, C. E., et al. (2024) · Drugs in R&D · doi:10.1007/s40268-024-00477-3 · Cited by 6
“The oral twice daily combination dextromethorphan/bupropion has been shown to be effective [22, 23] and has been recently FDA approved for the treatment of MDD [7, 8].”
BackgroundBozzatello, P., Novelli, R., Schisano, R., Brasso, C., Rocca, P., & Bellino, S. (2025) · Pharmaceuticals · doi:10.3390/ph18050665 · Cited by 8
“Another randomized, double-blind, clinical trial conducted by Tabuteau et al. [32] evaluated the difference in efficacy between dex-tromethorphan/bupropion vs. bupropion in a total sample of 80 patients with MDD. MADRS assessed the clinical improvement.”
López‐Arnau, R., Camarasa, J., Carbó, M., Nadal‐Gratacós, N., Puigseslloses, P., Espinosa‐Velasco, M., Urquizu, E., Escubedo, E., & Pubill, D. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.990405 · Cited by 7
Perspectives on the success rate of current antidepressant pharmacotherapy
Goldberg, J. F. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2138333 · Cited by 8
“receptor antagonists beyond ketamine, such as esmethadone [96] and dextromethorphan-bupropion [97]; neurosteroids such as zuranolone [98]; and psychedelics that are believed to enhance neuroplasticity such as psilocybin [99].”
BackgroundDextromethorphan: From Cough Suppressant to Antidepressant
Kverno, K. S. (2022) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20221005-02 · Cited by 6
Depression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
Glucagon-Like Peptide-1 Receptor Agonists for Mood Disorders and Suicide Risk
McIntyre, R. S. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.04.019 · Cited by 7
Better Biomarkers, Faster Drugs, Stronger Models: Progress Towards Precision Psychiatry.
Siegel, J. S., Pearson, C. S., & Lenze, E. J. (2023) · PubMed Central · Cited by 6
Overview of approved psychiatric medications 2008-2023: A systematic review
IsHak, W. W., Totlani, J., Murphy, N., Renteria, S., Chang, T. Y., Abdelsalam, R., Salem, M., Meyer, A., Khan, R., Chandy, T., et al. (2024) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2024.21.3.0705 · Cited by 5
Learning how to make use of dissociative therapies
Mathai, D. S. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2406329 · Cited by 6
“Dextromethorphan-bupropion was similarly approved by the FDA as an antidepressant based on short-term efficacy data from just one positive study using an inactive placebo (Iosifescu et al., 2022), and a second study that used bupropion as an active comparator (Tabuteau et al., 2022).”
Maji, S., Mishra, A., Mohapatra, D., Mishra, B. R., Jena, M., Srinivasan, A., & Maiti, R. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116257 · Cited by 5
Dextromethorphan/bupropion in major depressive disorder: a profile of its use
Blair, H. A. (2023) · Drugs & Therapy Perspectives · doi:10.1007/s40267-023-01009-w · Cited by 5
“Dextromethorphan/bupropion significantly improves depressive symptoms in adults with MDD [8, 9].”
BackgroundMethodResultInfluentialBhatti, N. A., Jobilal, A., Asif, K., Villegas, M. J., Pandey, P., Tahir, A. N., Balla, N. V. D. B., Camargo, M. P. A., Ahmad, S., Kataria, J., et al. (2023) · Cureus · doi:10.7759/cureus.44038 · Cited by 6
Blanco, J., Quimbaya, P., Mena, M., Dodd, S., & Bustos, R. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2374024 · Cited by 6
“Main side effects reported for the combination of DXM plus bupropion are dizziness, nausea, headache, diarrhea, somnolence, decreased appetite, anxiety and dry mouth [50,55].”
InfluentialGupta, L., Tomar, N., & Sarin, R. K. (2024) · Emerging Trends in Drugs Addictions and Health · doi:10.1016/j.etdah.2024.100161 · Cited by 9
Pappagallo, M., Kosten, T. R., Gorodetzky, C. W., Vocci, F. J., Sapienza, F. L., Martin, S. D., Comai, S., Mattarei, A., Inturrisi, C. E., & Manfredi, P. L. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02621-6 · Cited by 5
Effects of bupropion on sign- and goal-tracking in male Sprague Dawley rats
Holden, J. M. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.114241 · Cited by 4
Opioids-Induced Long QT Syndrome: A Challenge to Cardiac Health
Hu, J., Song, Y., Huang, X., Li, C., Jin, X., Cen, L., Zhang, C., Ding, B., & Lian, J. (2024) · Cardiovascular Toxicology · doi:10.1007/s12012-024-09853-6 · Cited by 10
“Recent studies have surfaced that dextromethorphan, in addition to its cough sup-pressant effects, may have a favorable therapeutic effect on major depression in adults [61, 62].”
BackgroundMaji, S., Mohapatra, D., Jena, M., Srinivasan, A., & Maiti, R. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-080500 · Cited by 4
Fixed dose combination dextromethorphan-bupropion: A hope for treatment resistant depression (TRD)
Das, R., Chakravarty, R., Gantait, V., & Bhattacharjee, S. (2025) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry_315_25 · Cited by 4
Intentional overdose of a novel dextromethorphan-bupropion combination antidepressant
Lothet, E., Fredrickson, C., Nguyen, K.-L., Bertels, K., & Mullins, M. E. (2023) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2023.08.026 · Cited by 4
The pharmacological management of treatment-resistant depression: what does the future hold?
Serretti, A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2287011 · Cited by 4
“This is an interesting example of a new use of drugs that were already on the market, but when used in combination they offer a number of mutual benefits, resulting in a much faster, more robust and broader effect than bupropion alone, due to pharmacokinetic and pharmacodynamic interactions [15,16].”
BackgroundTargeting Neuroinflammation in Depression: The Integrative Role of Sigma‐1 Receptor Modulation
Wang, J., Yang, D., Li, Y., & Ren, P. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70490 · Cited by 3
Newly FDA-approved psychotropic medications
Naguy, A., PRIDMORE, S. A., & Alamiri, B. (2022) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2022.103275 · Cited by 3
The “new wave” of antidepressants: are these agents paradigm-shifters in treating major depression?
Petrescu, B. M., Marinescu, I. P., Marinescu, D., Vasiliu, O., Mangalagiu, A. G., & Cândea, C. A. (2023) · Psihiatru ro · doi:10.26416/psih.75.4.2023.8926 · Cited by 4
Yuan, L., He, J., & Li, X. (2025) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-025-03841-7 · Cited by 3
Pan, P., & Yeh, C. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119546 · Cited by 2
Ashwin, J. V., Shahi, M. K., Singh, A., & Kumar, S. (2025) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_907_24 · Cited by 5
“Both the study by Tabuteau et al. (2022) [15] and Iosifescu et al. (2022) [6] were judged to have a low RoB across all domains.”
InfluentialAdvances in the study of pharmacotherapy for addiction to naturally-derived psychoactive substances
Xie, K., Xiao, D., Xu, P., Shen, H., & Di, B. (2025) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(25)60831-4 · Cited by 7
Teopiz, K. M., Le, G. H., Wong, S., & McIntyre, R. S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120836 · Cited by 2
Le, G. H., & McIntyre, R. S. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2619757 · Cited by 4
“Pharmacokinetic context may influence the magnitude and duration of NMDA receptor inhibition without altering the identify of DXM as the NMDA receptor-active component of the formulation [113].”
Piechal, A., Jakimiuk, A. A., & Pyrzanowska, J. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00852-8 · Cited by 2
An Update on Somatic Treatments for Suicide Risk
Rizk, M., & Mann, J. J. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20260287 · Cited by 4
Gaca, Z., Pruc, M., Świeczkowski, D., Kwaśny, A., Szarpak, Ł., & Cubała, W. J. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.04.016 · Cited by 2
“Current and emerging drug therapies in Alzheimer’s disease: A pathophysiological Perspective”
Aparajita, A., Jain, U., & Srivastava, P. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.11.078 · Cited by 2
de Miranda, A. S., Toscano, E. C. D. B., Venna, V. R., Graeff, F. G., & Teixeira, A. L. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2460674 · Cited by 4
“This combination was approved for MDD by the FDA [79,80].”
Naher, S. (2023) · Journal of Sociology Psychology & Religious Studies · doi:10.53819/81018102t4218 · Cited by 1
Structural basis of connexin-36 gap junction channel inhibitionPreprint
Ding, X., Aureli, S., Vaithia, A., Lavriha, P., Schuster, D., Khanppnavar, B., Li, X., Blum, T. B., Picotti, P., Gervasio, F. L., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.09.570920 · Cited by 2
Regen, F., & Benkert, O. (2023) · Springer eBooks · doi:10.1007/978-3-662-67685-1_1 · Cited by 1
Zhang, L., Bao, D., & Wang, C. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116490 · Cited by 1
Metadata
- Authors
- Tabuteau, H., Jones, A., Anderson, A., Jacobson, M., & Iosifescu, D. V.
- Affiliations
- Axsome Therapeutics (United States) (US)
- ORCID
- Iosifescu, Dan V.
- Venue
- American Journal of Psychiatry
- Published
- 2022-07-01
- Volume
- 179
- Issue
- 7
- Pages
- 490-499
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W4280521929
- Cited by
- 140
- References
- 31
- Citations by year
- 2026: 22 · 2025: 37 · 2024: 33 · 2023: 34 · 2022: 14
- FWCI
- 17.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- major depressive disorder, NMDA receptor antagonists, sigma-1 receptor agonist, bupropion, CYP2D6 inhibition, glutamatergic neurotransmission, antidepressant efficacy, remission, treatment safety, adverse events, antidepressant drug development
- MeSH terms
- Adolescent, Adult, Aged, Major Depressive Disorder, Depressive Disorder, Major, Dextromethorphan, Double-Blind Method, Humans, Middle Aged, Bupropion, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.